EyePoint Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q3 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
EyePoint Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q3 2010 to Q3 2024.
  • EyePoint Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$29.4M, a 133% decline year-over-year.
  • EyePoint Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$104M, a 3.42% decline year-over-year.
  • EyePoint Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$70.8M, a 30.8% increase from 2022.
  • EyePoint Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$102M, a 75% decline from 2021.
  • EyePoint Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$58.4M, a 28.7% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$104M -$29.4M -$16.7M -133% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$86.8M -$30.8M -$7.91M -34.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$78.9M -$29.3M -$8.12M -38.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$70.8M -$14.1M +$29.4M +67.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-08
Q3 2023 -$100M -$12.6M +$5.81M +31.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$106M -$22.9M -$3.51M -18.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$102M -$21.2M -$188K -0.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$102M -$43.5M -$24M -124% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-08
Q3 2022 -$78.2M -$18.4M -$1.73M -10.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 -$76.5M -$19.4M -$9.4M -93.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-04
Q1 2022 -$67.1M -$21M -$8.7M -70.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$58.4M -$19.4M -$3.96M -25.6% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-10
Q3 2021 -$54.5M -$16.7M -$12.9M -339% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-04
Q2 2021 -$41.6M -$10M +$2.94M +22.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-05
Q1 2021 -$44.5M -$12.3M +$894K +6.79% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 -$45.4M -$15.5M -$5.06M -48.6% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-14
Q3 2020 -$40.3M -$3.8M +$11.8M +75.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 -$52.2M -$13M -$1.45M -12.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q1 2020 -$50.7M -$13.2M +$6.06M +31.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 -$56.8M -$10.4M +$1.18M +10.2% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-16
Q3 2019 -$58M -$15.6M +$17.5M +52.8% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 -$75.5M -$11.5M +$22.9M +66.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 -$98.4M -$19.2M -$12.3M -176% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 -$86.1M -$11.6M -$5.81M -101% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-16
Q3 2018 -$80.3M -$33.1M -$27.1M -454% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-16
Q2 2018 -$53.2M -$34.4M -$28.3M -463% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-16
Q1 2018 -$24.9M -$6.98M -$1.84M -35.8% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-16
Q4 2017 -$23M -$5.78M -$5.72M -8530% Oct 1, 2017 Dec 31, 2017 10-K 2020-03-16
Q3 2017 -$17.3M -$5.98M +$1.18M +16.5% Jul 1, 2017 Sep 30, 2017 10-K 2020-03-16
Q2 2017 -$18.5M -$6.12M +$271K +4.24% Apr 1, 2017 Jun 30, 2017 10-KT 2019-03-18
Q1 2017 -$18.8M -$5.14M -$99K -1.96% Jan 1, 2017 Mar 31, 2017 10-KT 2019-03-18
Q4 2016 -$18.7M -$67K +$5.12M +98.7% Oct 1, 2016 Dec 31, 2016 10-K 2018-09-18
Q3 2016 -$23.8M -$7.16M -$2.23M -45.2% Jul 1, 2016 Sep 30, 2016 10-KT 2019-03-18
Q2 2016 -$21.5M -$6.39M -$1.24M -24.1% Apr 1, 2016 Jun 30, 2016 10-K 2017-09-13
Q1 2016 -$20.3M -$5.04M -$43K -0.86% Jan 1, 2016 Mar 31, 2016 10-K 2017-09-13
Q4 2015 -$20.3M -$5.19M -$1.11M -27.3% Oct 1, 2015 Dec 31, 2015 10-K 2017-09-13
Q3 2015 -$19.2M -$4.93M -$25.5M -124% Jul 1, 2015 Sep 30, 2015 10-K 2017-09-13
Q2 2015 $6.35M -$5.15M -$1.18M -29.7% Apr 1, 2015 Jun 30, 2015 10-K 2016-09-13
Q1 2015 $7.53M -$5M -$2.81M -129% Jan 1, 2015 Mar 31, 2015 10-K 2016-09-13
Q4 2014 $10.3M -$4.08M -$561K -16% Oct 1, 2014 Dec 31, 2014 10-K 2016-09-13
Q3 2014 $10.9M $20.6M +$24.3M Jul 1, 2014 Sep 30, 2014 10-K 2016-09-13
Q2 2014 -$13.4M -$3.97M -$20K -0.51% Apr 1, 2014 Jun 30, 2014 10-K 2015-09-10
Q1 2014 -$13.3M -$2.19M +$607K +21.7% Jan 1, 2014 Mar 31, 2014 10-K 2015-09-10
Q4 2013 -$13.9M -$3.51M -$906K -34.7% Oct 1, 2013 Dec 31, 2013 10-K 2015-09-10
Q3 2013 -$13M -$3.69M -$1.14M -44.5% Jul 1, 2013 Sep 30, 2013 10-K 2015-09-10
Q2 2013 -$11.9M -$3.95M -$1.69M -74.5% Apr 1, 2013 Jun 30, 2013 10-K 2014-09-11
Q1 2013 -$10.2M -$2.79M -$108K -4.02% Jan 1, 2013 Mar 31, 2013 10-K 2014-09-11
Q4 2012 -$10.1M -$2.61M +$14.9M +85.1% Oct 1, 2012 Dec 31, 2012 10-K 2014-09-11
Q3 2012 -$25M -$2.55M -$124K -5.11% Jul 1, 2012 Sep 30, 2012 10-K 2014-09-11
Q2 2012 -$24.8M -$2.26M -$2.12M -1516% Apr 1, 2012 Jun 30, 2012 10-K 2013-09-27
Q1 2012 -$22.7M -$2.69M -$1K -0.04% Jan 1, 2012 Mar 31, 2012 10-K 2013-09-27
Q4 2011 -$22.7M -$17.5M -$14.8M -548% Oct 1, 2011 Dec 31, 2011 10-K 2013-09-27
Q3 2011 -$7.95M -$2.43M +$681K +21.9% Jul 1, 2011 Sep 30, 2011 10-K 2013-09-27
Q2 2011 -$8.63M -$140K Apr 1, 2011 Jun 30, 2011 10-K 2012-09-27
Q1 2011 -$2.69M Jan 1, 2011 Mar 31, 2011 10-K 2012-09-27
Q4 2010 -$2.7M Oct 1, 2010 Dec 31, 2010 10-K 2012-09-27
Q3 2010 -$3.11M Jul 1, 2010 Sep 30, 2010 10-K 2012-09-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.